Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Lamotrigine vs BIORPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Bipolar I disorder (maintenance treatment),Partial-onset seizures (adjunctive therapy),Primary generalized tonic-clonic seizures (adjunctive therapy),Lennox-Gastaut syndrome (seizures),Off-label: neuropathic pain, trigeminal neuralgia, schizophrenia augmentation
Treatment of hypotension during anesthesia,Treatment of mild to moderate hypotension,Vasopressor support in shock states (off-label),Management of paroxysmal supraventricular tachycardia (off-label)
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Primarily metabolized by UDP-glucuronosyltransferases (UGT1A4, UGT2B7). Minimal involvement of CYP450 enzymes. Autoinduction of its own metabolism with chronic use.
Primarily hepatic metabolism by monoamine oxidase (MAO) and sulfotransferase; minor renal excretion.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
55% (binds to albumin)
~35% bound to albumin.
1.2 L/kg (distribution into tissues, including brain)
Vd: 3–5 L/kg (large distribution indicates extensive tissue uptake, e.g., brain, fat).
Oral: 98% (immediate-release); ~90% (extended-release)
Oral: 50–60% (first-pass); Rectal: ~50%; IM/IV: 100%.
e GFR <30 m L/min/1.73 m²: use with caution; no specific dose adjustment recommended. e GFR <10 m L/min: reduce dose by 50% and monitor.
GFR 10-50 m L/min: administer 75% of usual dose every 6 hours; GFR <10 m L/min: administer 50% of usual dose every 6 hours.
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
2-12 years: 0.15 mg/kg/day once daily for 2 weeks, then 0.3 mg/kg/day once daily for 2 weeks, then increase by 0.3 mg/kg/day every 1-2 weeks. Maintenance: 1-5 mg/kg/day divided twice daily. Maximum: 400 mg/day.
Children: 0.1-0.2 mg/kg IV/IM/SC every 2-4 hours as needed; oral: 0.3-0.5 mg/kg every 4-6 hours as needed. Maximum single dose: 15 mg.
Lower initial doses (25 mg every other day) and slower titration due to increased sensitivity and slower clearance; monitor for adverse effects.
Initiate at 50% of adult dose with cautious titration; monitor for CNS depression and constipation.
Life-threatening rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially in pediatric patients and with rapid dose escalation.
No FDA boxed warning.
Risk of serious rash (SJS/TEN); hemophagocytic lymphohistiocytosis (HLH); aseptic meningitis; multiorgan hypersensitivity reactions; suicidal thoughts and behavior; blood dyscrasias; cardiac conduction abnormalities; increased seizure frequency with abrupt withdrawal.
May cause severe hypertension and bradycardia,Use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis,Risk of extravasation with local tissue necrosis,Monitor blood pressure continuously during administration,May exacerbate angle-closure glaucoma
Hypersensitivity to lamotrigine or any component of the formulation.
Hypersensitivity to phenylephrine or any component,Severe hypertension,Ventricular tachycardia,Patients receiving monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy
No significant food interactions. Grapefruit has no effect. Alcohol may increase CNS depression and dizziness; limit or avoid.
No food interactions known; BIORPHEN is topical and not systemically absorbed.
First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac malformations, and developmental delay. Higher doses (>300 mg/day) and polytherapy increase risk. Folate supplementation recommended.
BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal withdrawal, respiratory depression, and sedation due to placental transfer and fetal accumulation. Use only if clearly needed and no safer alternative exists.
Lamotrigine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6. Infant serum concentrations can reach 25-50% of maternal levels. Risk of rash, apnea, drowsiness; benefits likely outweigh risks in most cases. Monitor infant for adverse effects.
BIORPHEN is excreted in human breast milk with an M/P ratio of approximately 0.7. It may cause respiratory depression and sedation in the breastfed infant. Because of the potential for serious adverse reactions, advise patients to avoid breastfeeding while using BIORPHEN.
Clearance increases by 50-330% during pregnancy, particularly in second and third trimesters. Dose may need to be increased (up to 2-3 times pre-pregnancy dose) to maintain therapeutic levels. Postpartum clearance returns to baseline within 1-2 weeks, requiring dose reduction to avoid toxicity.
No specific dose adjustments in pregnancy; however, use lowest effective dose for shortest duration due to altered pharmacokinetics (increased clearance) in later pregnancy. Taper dose gradually to avoid maternal withdrawal.
Titrate slowly to minimize risk of Stevens-Johnson syndrome; start 25 mg/day for weeks 1–2, then 50 mg/day for weeks 3–4. Drug interactions: valproate doubles lamotrigine half-life and increases SJS risk; estrogen-containing contraceptives reduce lamotrigine levels by ~50%. Therapeutic serum level: 2.5–15 mcg/m L. Monitor for rash, especially in first 8 weeks.
BIORPHEN (bioresmethrin) is a pyrethroid insecticide used topically for pediculosis. Avoid contact with eyes and mucous membranes. Do not use on open wounds or broken skin. Reapply after 7-10 days if live lice persist. Resistance is rare but monitor efficacy.
Report any rash, hives, or blisters immediately; may be sign of serious skin reaction.,Do not stop taking abruptly; taper under doctor's guidance to avoid rebound seizures.,Take missed dose as soon as remembered unless close to next dose; do not double.,Oral contraceptives and hormone therapy can reduce lamotrigine effectiveness; discuss with doctor.,Avoid driving or operating machinery until effects are known; may cause dizziness or blurred vision.
Apply only to dry hair and scalp, avoiding eyes.,Leave on for 10 minutes, then rinse thoroughly.,Use a fine-toothed comb to remove nits.,Do not use more than once daily or exceed recommended duration.,Wash bedding and clothing in hot water.,Inform doctor if itching or irritation persists.
"Telithromycin is a potent inhibitor of CYP3A4, while lamotrigine is primarily metabolized by UGT1A4 and not significantly by CYP3A4. However, telithromycin may also inhibit UGT1A4, leading to reduced lamotrigine clearance and increased risk of lamotrigine toxicity, including severe rash (Stevens-Johnson syndrome) and central nervous system depression. Concurrent use may require lamotrigine dose adjustment to avoid adverse effects."
"Concomitant use of Lormetazepam, a benzodiazepine that enhances GABAergic inhibition, and Lamotrigine, a sodium channel blocker and glutamate release inhibitor, may result in additive central nervous system depression and an increased risk of sedation, dizziness, and psychomotor impairment. The interaction is primarily pharmacodynamic, as both drugs have CNS depressant effects, potentially leading to excessive drowsiness and impaired coordination. Clinical outcomes may include increased fall risk, cognitive dysfunction, and compromised ability to perform tasks requiring alertness."
"Concurrent use of paliperidone and lamotrigine may increase the risk of central nervous system depression and synergistic adverse effects, including sedation, dizziness, and impaired cognitive function. Paliperidone, an atypical antipsychotic, and lamotrigine, an anticonvulsant, both modulate neurotransmitter systems, potentially leading to additive pharmacodynamic effects. Clinically, this can result in increased sedation, confusion, and an elevated risk of falls or accidents, particularly in elderly patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Lamotrigine vs BIORPHEN, answered by our medical review team.
Lamotrigine is a Anticonvulsant that works by Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.. BIORPHEN is a Anticonvulsant that works by Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Lamotrigine and BIORPHEN depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Lamotrigine is: Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.. The standard adult dose of BIORPHEN is: Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Lamotrigine and BIORPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Lamotrigine is classified as Category A/B. First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac. BIORPHEN is classified as Category C. BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.